Journals / The Anatolian Journal of Cardiology / 2018 / Cilt: 20 - Sayı: 1

Pulmonary hypertension experience in an expert university hospital

Pages
35–40
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In group 1 PH,45.7% of patients (n=64) were classified as having idiopathic PAH (IPAH) after excluding the alternative diagnosis using PH diagnostic algorithm.The remaining 54.3% of group 1 PH patients (n=76) had various diseases that caused PAH, which is called associated PAH (APAH); APAH groupincluded PAH associated with congenital heart diseases (n=70), connective tissue disorders (scleroderma, n=4) and portal hypertension (n=2).Conclusion: Our data provides important information in real-life settings in terms of demographics, clinical course, PH subgroup distribution, andtreatment patterns in patients with PAH in a reference tertiary center in Turkey.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Pulmonary artery hypertension (PAH) is characterized by remodeling of the small pulmonary arteries, leading to a progressive increasein pulmonary vascular resistance and right ventricular failure.
📊
Key Findings & Data:In this study, we aimed to share our 10 years of experience dealing withpulmonary hypertension (PH) and provide information in real-life settings in terms of demographics, clinical course, PH subgroup distribution,and treatment patterns in patients with PAH in a tertiary center.Methods: In this retrospective, single-center, observational study, we screened the patients who applied to PH outpatient clinic of İstanbulUniversity Institute of Cardiology due to the suspicion of PAH between 2008 and 2017.
💡
Conclusion & Impact:In group 1 PH,45.7% of patients (n=64) were classified as having idiopathic PAH (IPAH) after excluding the alternative diagnosis using PH diagnostic algorithm.The remaining 54.3% of group 1 PH patients (n=76) had various diseases that caused PAH, which is called associated PAH (APAH); APAH groupincluded PAH associated with congenital heart diseases (n=70), connective tissue disorders (scleroderma, n=4) and portal hypertension (n=2).Conclusion: Our data provides important information in real-life settings in terms of demographics, clinical course, PH subgroup distribution, andtreatment patterns in patients with PAH in a reference tertiary center in Turkey.
🔬Design:Modeling & Simulation
📍Scope:2008 Verileri
⚙️Variables:Domain Parameters

Özet

Objective: Pulmonary artery hypertension (PAH) is characterized by remodeling of the small pulmonary arteries, leading to a progressive increasein pulmonary vascular resistance and right ventricular failure. In this study, we aimed to share our 10 years of experience dealing withpulmonary hypertension (PH) and provide information in real-life settings in terms of demographics, clinical course, PH subgroup distribution,and treatment patterns in patients with PAH in a tertiary center.Methods: In this retrospective, single-center, observational study, we screened the patients who applied to PH outpatient clinic of İstanbulUniversity Institute of Cardiology due to the suspicion of PAH between 2008 and 2017. While group 1, 4, and 5 PH patients were included, group2 and 3 PH patients were excluded from the study.Results: Our study group comprised 162 patients (115 females, 71%). The female:male ratio was 2.4. The mean age was 52±16 years. Most (86.4%)of the patients were in group 1 PH (PAH). The rest (13.6%, n=22) of the patients were in group 4 PH (chronic thromboembolic PH). In group 1 PH,45.7% of patients (n=64) were classified as having idiopathic PAH (IPAH) after excluding the alternative diagnosis using PH diagnostic algorithm.The remaining 54.3% of group 1 PH patients (n=76) had various diseases that caused PAH, which is called associated PAH (APAH); APAH groupincluded PAH associated with congenital heart diseases (n=70), connective tissue disorders (scleroderma, n=4) and portal hypertension (n=2).Conclusion: Our data provides important information in real-life settings in terms of demographics, clinical course, PH subgroup distribution, andtreatment patterns in patients with PAH in a reference tertiary center in Turkey.

🔖

Cite This Article

SİNAN, Ü. Y., DEMİR, R., CANBOLAT, İ. P., PALABIYIK, M., KAYA, A., KÜÇÜKOĞLU, M. S. (2018). Pulmonary hypertension experience in an expert university hospital. The Anatolian Journal of Cardiology, Cilt: 20 - Sayı: 1, 35–40. https://ajindex.com/articles/365304

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Manes A, Palazzini M, Leci E, Bacchi Reggiani ML, Branzi A, Galiè N. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J 2014; 35: 716-24. [CrossRef] Palazzini M, Leci E, Bachetti C, Conficoni E, Mazzanti G, Gotti E, et al. Current era survival of PAH patients: comparison between clinical subgroups. Eur Heart J 2010; 31 (Abstract Supplement): 21. Kayıkçıoğlu M, Kültürsay H. Seven years of experience in patients with pulmonary arterial hypertension in Ege University Hospital: diagnostic approach of a single center. Anatol J Cardiol 2008; 8: 279-85.
  2. Kaymaz C, Mutlu B, Küçükoğlu MS, Kaya B, Akdeniz B, Kılıçkıran Avcı B, et al. Preliminary results from a nationwide adult cardiology perspective for pulmonary hypertension: RegiStry on clInical outcoMe and sUrvival in pulmonaRy hypertension Groups (SIMURG). Anatol J Cardiol 2017; 18: 242-50. [CrossRef] Lee WT, Ling Y, Sheares KK, Pepke-Zaba J, Peacock AJ, Johnson MK. Predicting survival in pulmonary arterial hypertension in the UK. Eur Respir J 2012; 40: 604-11. [CrossRef] Hoeper MM, Huscher D, Ghofrani HA, Delcroix M, Distler O, Schweiger C, et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol 2013; 168: 871-80. [CrossRef] Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164-72. [CrossRef] Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 2010; 35: 1079-87.
  3. Zhang R, Dai LZ, Xie WP, Yu ZX, Wu BX, Pan L, et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era. Chest 2011; 140: 301-9. [CrossRef] Jing ZC, Xu Xo, Han ZY, Wu Y, Deng KW, Wang H, et al. Registry and survival study in Chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest 2007; 132: 373-9. [CrossRef] Jansa P, Jarkovsky J, Al-Hiti H, Popelova J, Ambroz D, Zatocil T, et al. Eidemiology and long term survival of pulmonary artery hypertension in the Czech Republic: a retrospective analysis of a nationwide registry. BMC Pulm Med 2014; 14: